Soren Weis Dahl work email
- Valid
- Valid
Soren Weis Dahl personal email
- Valid
Soren Weis Dahl phone numbers
Biopharmaceutical Executive - Recently completed my mission as CEO of Prophylix by delivering investor exit in transaction with the top-tier US orphan drug specialist Rallybio. One of Prophylix's former assets, RLYB211, is now Rallybio’s lead project and critical in securing their recent $145 m series B round. My career-long life science and business experience in the US and Europe includes biotech strategy and business development, biotech consulting, and project management. At Prophylix, I have guided virtually all aspects of the company—strategic, business development, operational, financial, regulatory, organizational staffing, and more—and have combined these pieces in ambitious and executable strategies. Furthermore, I have led negotiations of licensing, partnership and M&A transactions worth 8- to 9-figure dollars in collaboration with EU and US attorneys. With a strong commercial mindset, I establish and cultivate global strategic partnerships to accelerate and strengthen R&D and maximize value creation. Key areas of experience include licensing, contracting, outsourcing, and integration. I see issues and opportunities, and conceive innovative ways forward, driving new solutions in the face of challenges, complexity, and risk.US permanent resident (Green Card) and Danish citizen.
-
Chief Executive OfficerGambit Bio LlcWaltham, Ma, Us
-
Chief Business OfficerAxcynsis Therapeutics Dec 2024 - PresentSupporting Axcynsis' development of its IND-stage ADC therapeutics employing Axcynsis' proprietary, first-in-class AxcynDOT payload -
Chief Executive OfficerGambit Bio Llc Oct 2019 - PresentConsultancy providing strategy and business development and investment advisory services to life science investors and companies. Search and evaluation of late preclinical and early clinical opportunities.
-
Director Board Of DirectorsProphylix Pharma Holding As Sep 2019 - Present -
Director Board Of DirectorsPila Pharma May 2023 - Apr 2024Malmö, Skåne County, SeDirector on the board with special insights into orphan drug development and US opportunities -
Chief Executive OfficerDecktherapeutics, Inc. Dec 2020 - Apr 2024Led Columbia University spinout DeckTherapeutics on its mission to pioneer neuroprotection using intravenous omega-3 diglyceride therapeutics. Secured funding from two institutional investors and a non-dilutive grant from the Bill & Melinda Gates Foundation. Oversaw the progression of the lead asset to late preclinical stage. -
Chief Executive OfficerProphylix As Apr 2015 - Sep 2019Tromsø, Troms, NoLed strategy, and business and organizational development to drive evolution to clinical-stage, orphan drug company and investor exit in transaction with US orphan drug specialist Rallybio (www.rallybio.com). Established and managed vital relationships with CMC, development, and commercial partners. Drove strategy to obtain dual FDA/EMA compliant product and secure feasible path to US and European markets. -
Chief Business OfficerProphylix As Aug 2013 - Mar 2015Tromsø, Troms, NoDrove regulatory and partnering strategy development and implementation across North America and Europe. Steered subcontracting of drug manufacturing. Developed organization to a near-clinical stage company. Led investor presentations and interactions.
-
Eu Project CoordinatorProphylix As Jun 2012 - Jul 2013Tromsø, Troms, NoCoordinator of the EU FP-7 project PROFNAIT (www.profnait.eu). The 11 organizations in the Northern European consortium seek to develop a new prophylactic treatment of the rare disease fetal/neonatal alloimmune thrombocytopenia (FNAIT).
-
PresidentProphylix Pharma Inc Oct 2013 - Sep 2019Established and led US drug and business development activities. Built and managed key alliances, including with medical advisors, plasma suppliers, drug manufacturer, consultants, investors, regulators and other stakeholders based in North America.
-
Senior ConsultantWiborg Aps Aug 2009 - Jul 2013Hørsholm, DkConsulted to diverse companies on biotech strategy and business development, scientific and commercial assessments/due diligence, valuations and deal structuring. Contributed directly to business transformation and investment decisions. Authored successful orphan drug applications to EMA and FDA. -
Senior Project Manager, Corporate Project Management OfficeDako May 2007 - Jul 2008Glostrup, DkManaged a large, international reagents development and pre-marketing project. Aligned development processes and quality standards across two countries, and achieved full integration on automated platform. Delivered product line launch on time and on budget. Dako is now Agilent Technologies. -
Process Specialist, Regulatory AffairsLeo Pharma Dec 2006 - Apr 2007Ballerup, Dk, DkDrove balanced scorecard and user requirement specifications for PV database. -
Senior Project ManagerLeo Pharma Apr 2005 - Nov 2006Ballerup, Dk, DkLed implementation of formal project management in Discovery organization, steering committee facilitation, and optimization of process for scientific assessment of in-licensing opportunities.
-
Project ManagerBioimage Nov 2000 - Mar 2005DkFull-time project management and commercialization of drug discovery projects. Represented company in commercial discussions with AstraZeneca, Becton Dickinson, Schering, and more. -
Research ScientistUnizyme Laboratories A/S Aug 1996 - Oct 2000Performed gene cloning and engineering and protein expression, purification, and characterization. Drove external collaborations with academic groups that led the first X-ray structures of a 160,000 kDa dipeptidyl peptidase.
Soren Weis Dahl Skills
Soren Weis Dahl Education Details
-
Copenhagen Business SchoolGeneral -
Dtu - Technical University Of DenmarkMolecular Biology And Recombinant Protein Chemistry
Frequently Asked Questions about Soren Weis Dahl
What company does Soren Weis Dahl work for?
Soren Weis Dahl works for Gambit Bio Llc
What is Soren Weis Dahl's role at the current company?
Soren Weis Dahl's current role is Chief Executive Officer.
What is Soren Weis Dahl's email address?
Soren Weis Dahl's email address is we****@****ail.com
What is Soren Weis Dahl's direct phone number?
Soren Weis Dahl's direct phone number is +164627*****
What schools did Soren Weis Dahl attend?
Soren Weis Dahl attended Copenhagen Business School, Dtu - Technical University Of Denmark.
What skills is Soren Weis Dahl known for?
Soren Weis Dahl has skills like Biotechnology, Strategy, Lifesciences, Drug Discovery, Business Development, Pharmaceutical Industry, Life Sciences, Commercialization, Management, Technology Transfer, Project Management, Biopharmaceuticals.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial